A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma

NCT07446335 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

578

Enrollment

OTHER

Sponsor class

Conditions

Advanced Esophageal Squamous Cell Carcinoma

Interventions

DRUG: anlotinib combined with benmelstobart
DRUG: Toripalimab Combined with Chemotherapy

Sponsor

The First Affiliated Hospital of Zhengzhou University